Gan & Lee Pharmaceuticals. (SHA:603087)
China · Delayed Price · Currency is CNY 60.14
+0.16 (0.27%)
May 8, 2026, 3:00 PM CST
SHA:603087 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,945 | 4,052 | 3,034 | 2,596 | 1,710 | 3,612 |
Other Revenue | - | - | 11.4 | 11.6 | 2.4 | 0.11 |
| 3,945 | 4,052 | 3,045 | 2,608 | 1,712 | 3,612 | |
Revenue Growth (YoY) | 13.70% | 33.06% | 16.77% | 52.31% | -52.60% | 7.44% |
Cost of Revenue | 973.44 | 978.95 | 777.15 | 724.7 | 443.93 | 399.9 |
Gross Profit | 2,972 | 3,073 | 2,268 | 1,883 | 1,268 | 3,212 |
Selling, General & Admin | 1,550 | 1,619 | 1,423 | 1,163 | 1,334 | 1,302 |
Research & Development | 644.57 | 646.97 | 541.05 | 501.02 | 562.47 | 474.59 |
Other Operating Expenses | 17 | 13.26 | 29.83 | 23.61 | 20.37 | 26.21 |
Operating Expenses | 2,212 | 2,280 | 1,974 | 1,703 | 1,944 | 1,822 |
Operating Income | 759.98 | 793.63 | 294.58 | 180.03 | -675.68 | 1,390 |
Interest Expense | - | - | -0.29 | -0.55 | -0.78 | -0.96 |
Interest & Investment Income | 291.9 | 290.78 | 153.46 | 141.01 | 186.63 | 321.99 |
Currency Exchange Gain (Loss) | - | - | 6.61 | 2.4 | -2.39 | -0.71 |
Other Non Operating Income (Expenses) | 28.99 | 103.99 | -2.03 | -0.8 | -1.6 | -3.34 |
EBT Excluding Unusual Items | 1,081 | 1,188 | 452.32 | 322.09 | -493.82 | 1,707 |
Gain (Loss) on Sale of Investments | 33.56 | 73.82 | 156.61 | -17.92 | -80.66 | -54.45 |
Gain (Loss) on Sale of Assets | 3.71 | 3.71 | 1.15 | -0.49 | -5.18 | -1.7 |
Asset Writedown | -36.08 | -36.13 | -5.02 | -12.55 | -40.92 | - |
Other Unusual Items | - | - | 25.32 | 15.01 | 38.1 | 44.96 |
Pretax Income | 1,082 | 1,230 | 630.39 | 306.14 | -582.47 | 1,696 |
Income Tax Expense | 57.93 | 86.22 | 15.72 | -34.09 | -142.96 | 243.26 |
Earnings From Continuing Operations | 1,024 | 1,144 | 614.66 | 340.23 | -439.52 | 1,453 |
Minority Interest in Earnings | 0.02 | - | 0 | -0.16 | 0 | 0 |
Net Income | 1,024 | 1,144 | 614.66 | 340.07 | -439.52 | 1,453 |
Net Income to Common | 1,024 | 1,144 | 614.66 | 340.07 | -439.52 | 1,453 |
Net Income Growth | 23.31% | 86.05% | 80.75% | - | - | 18.04% |
Shares Outstanding (Basic) | 591 | 593 | 591 | 567 | 563 | 561 |
Shares Outstanding (Diluted) | 591 | 593 | 591 | 567 | 563 | 561 |
Shares Change (YoY) | 0.52% | 0.26% | 4.28% | 0.58% | 0.46% | 5.28% |
EPS (Basic) | 1.73 | 1.93 | 1.04 | 0.60 | -0.78 | 2.59 |
EPS (Diluted) | 1.73 | 1.93 | 1.04 | 0.60 | -0.78 | 2.59 |
EPS Growth | 22.66% | 85.58% | 73.33% | - | - | 12.12% |
Free Cash Flow | -280.13 | -141.81 | 96.51 | -443.61 | -686.76 | 386.09 |
Free Cash Flow Per Share | -0.47 | -0.24 | 0.16 | -0.78 | -1.22 | 0.69 |
Dividend Per Share | - | - | 1.500 | 0.200 | - | 0.300 |
Dividend Growth | - | - | 650.00% | - | - | -25.00% |
Gross Margin | 75.33% | 75.84% | 74.48% | 72.21% | 74.07% | 88.93% |
Operating Margin | 19.26% | 19.59% | 9.67% | 6.90% | -39.46% | 38.49% |
Profit Margin | 25.96% | 28.22% | 20.18% | 13.04% | -25.67% | 40.22% |
Free Cash Flow Margin | -7.10% | -3.50% | 3.17% | -17.01% | -40.11% | 10.69% |
EBITDA | 1,075 | 1,096 | 545.57 | 400.79 | -479.87 | 1,571 |
EBITDA Margin | 27.24% | 27.04% | 17.91% | 15.37% | -28.03% | 43.49% |
D&A For EBITDA | 314.84 | 302.07 | 251 | 220.75 | 195.81 | 180.64 |
EBIT | 759.98 | 793.63 | 294.58 | 180.03 | -675.68 | 1,390 |
EBIT Margin | 19.26% | 19.59% | 9.67% | 6.90% | -39.46% | 38.49% |
Effective Tax Rate | 5.35% | 7.01% | 2.49% | - | - | 14.34% |
Revenue as Reported | - | - | 3,045 | 2,608 | 1,712 | 3,612 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.